| <H5>
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-INDENT: 21pt; mso-char-indent-count: 2.0"><FONT size=3><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">日前，蒂博泰克的</SPAN><SPAN lang=EN-US><FONT face=Calibri>Incivo (telaprevir)</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">与聚乙二醇干扰素</SPAN><SPAN lang=EN-US><FONT face=Calibri>&al</FONT><A href="http://www.chemdrug.com/tradeinfo/trade/10-91.html"><FONT face=Calibri color=#444444>PH</FONT></A><FONT face=Calibri>a;</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">和利巴韦林的联合获得欧盟批准，用于治疗成年人患有的</SPAN><SPAN lang=EN-US><FONT face=Calibri>agenotype-1</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">慢性丙型肝炎（</SPAN><SPAN lang=EN-US><FONT face=Calibri>HCV</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">）。</SPAN></FONT></P>
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=3><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"> 在之前的</SPAN><SPAN lang=EN-US><A href="http://www.chemdrug.com/"><SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"><SPAN lang=EN-US><FONT color=#800080>研究</FONT></SPAN></SPAN></A></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">中，包括之前对未经过治疗的和治疗失败的</SPAN><SPAN lang=EN-US><FONT face=Calibri>agenotype-1</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">慢性丙型肝炎患者的</SPAN><SPAN lang=EN-US><A href="http://www.chemdrug.com/"><SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"><SPAN lang=EN-US><FONT color=#800080>研究</FONT></SPAN></SPAN></A></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">，与用聚乙二醇干扰素</SPAN><SPAN lang=EN-US><FONT face=Calibri>&al</FONT><A href="http://www.chemdrug.com/tradeinfo/trade/10-91.html"><FONT face=Calibri color=#444444>PH</FONT></A><A href="http://www.chemdrug.com/tradeinfo/trade/10-91.html)a"><FONT face=Calibri color=#444444>a</FONT></A><FONT face=Calibri>;</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">和利巴韦林进行的</SPAN><SPAN lang=EN-US><A href="http://www.chemdrug.com/databases/db_3_1.html"><SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"><SPAN lang=EN-US><FONT color=#444444>标准</FONT></SPAN></SPAN></A></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">治疗相比，</SPAN><SPAN lang=EN-US><FONT face=Calibri>Incivo (telaprevir)</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">与聚乙二醇干扰素</SPAN><SPAN lang=EN-US><FONT face=Calibri>&al</FONT><A href="http://www.chemdrug.com/tradeinfo/trade/10-91.html"><FONT face=Calibri color=#444444>PH</FONT></A><FONT face=Calibri>a;</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">和利巴韦林的联合使得治愈率有较大进展。</SPAN></FONT></P>
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=3><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"> 欧盟的这项决定主要基于三期</SPAN><SPAN lang=EN-US><A href="http://www.chemdrug.com/"><SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"><SPAN lang=EN-US><FONT color=#800080>研究</FONT></SPAN></SPAN></A></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">的结果，主要是研究</SPAN><SPAN lang=EN-US><FONT face=Calibri>Incivo (telaprevir)</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">与聚乙二醇干扰素α和利巴韦林联合使用的效用及安全性。</SPAN></FONT></P>
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=3><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"> 这些</SPAN><SPAN lang=EN-US><A href="http://www.chemdrug.com/tradeinfo/trade/11.html"><SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"><SPAN lang=EN-US><FONT color=#444444>试验</FONT></SPAN></SPAN></A></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">的结果表明，与</SPAN><SPAN lang=EN-US><FONT face=Calibri>Incivo (telaprevir)</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">与聚乙二醇干扰素α和利巴韦林的联合治疗能提高治愈率相比，用聚乙二醇干扰素α和利巴韦林进行的</SPAN><SPAN lang=EN-US><A href="http://www.chemdrug.com/databases/db_3_1.html"><SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri"><SPAN lang=EN-US><FONT color=#444444>标准</FONT></SPAN></SPAN></A></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri">疗法治疗未经治疗的患者却能使病情复发。</SPAN></FONT></P>
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><FONT face=Calibri size=3> </FONT></o:p></SPAN></P></H5> |
